Avidity Biosciences Inc (NASDAQ: RNA) open the trading on Wednesday, with a bit cautious approach as it glided -0.85% to $25.64, before settling in for the price of $25.86 at the close. Taking a more long-term approach, RNA posted a 52-week range of $4.82-$27.66.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 148.90%. Meanwhile, its Annual Earning per share during the time was -57.60%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -10.57%. This publicly-traded company’s shares outstanding now amounts to $79.28 million, simultaneously with a float of $72.71 million. The organization now has a market capitalization sitting at $2.04 billion. At the time of writing, stock’s 50-day Moving Average stood at $19.15, while the 200-day Moving Average is $10.90.
Avidity Biosciences Inc (RNA) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Avidity Biosciences Inc’s current insider ownership accounts for 8.80%, in contrast to 98.38% institutional ownership. According to the most recent insider trade that took place on Apr 03 ’24, this organization’s Director sold 20,000 shares at the rate of 27.11, making the entire transaction reach 542,214 in total value, affecting insider ownership by 253,872. Preceding that transaction, on Apr 02 ’24, Company’s President and CEO sold 28,000 for 26.25, making the whole transaction’s value amount to 734,919. This particular insider is now the holder of 112,117 in total.
Avidity Biosciences Inc (RNA) Earnings and Revenue Records
So, what does the last quarter earnings report of the company that was made public on 12/30/2023 suggests? It has posted -$0.79 earnings per share (EPS) not meeting the forecaster’s viewpoint (set at -$0.66) by -$0.13. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.78 per share during the current fiscal year.
Avidity Biosciences Inc’s EPS decrease for this current 12-month fiscal period is -10.57% and is forecasted to reach -3.49 in the upcoming year.
Avidity Biosciences Inc (NASDAQ: RNA) Trading Performance Indicators
Let’s observe the current performance indicators for Avidity Biosciences Inc (RNA). It’s Quick Ratio in the last reported quarter now stands at 7.58. The Stock has managed to achieve an average true range (ATR) of 1.73. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 213.81.
In the same vein, RNA’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.90, a figure that is expected to reach -0.80 in the next quarter, and analysts are predicting that it will be -3.49 at the market close of one year from today.
Technical Analysis of Avidity Biosciences Inc (RNA)
[Avidity Biosciences Inc, RNA] recent stats showed that its last 5-days Average volume was poorer than the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 63.39% While, its Average True Range was 1.81.
Raw Stochastic average of Avidity Biosciences Inc (RNA) in the period of the previous 100 days is set at 90.81%, which indicates a major rise in contrast to 66.89% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 63.50% that was lower than 81.01% volatility it exhibited in the past 100-days period.
